443 Studies Now Enrolling
A Randomized, Double-Blinded, Placebo-Controlled Study of the Effect of XmAb5871 on Systemic Lupus Erythematosus Disease Activity
A study for patients with lupus using the study drug XmAb5871.
| Sponsor: | Xencor, Inc |
| Enrolling: | Male and Female Patients |
| Study Length: | 253 Days |
| Clinic Visits: | 20 |
| IRB Number: | AAAQ2955 |
| U.S. Govt. ID: | NCT02725515 |
| Contact: | Anca Askanase MD MPH: 212-305-0856 / ada20@cumc.columbia.edu |
Additional Study Information:
The purpose of this clinical trial is to learn about the ability of an experimental treatment XmAb5871 to maintain lupus disease activity improvement achieved by a brief course of disease-suppressing intramuscular (IM) steroid therapy in lupus patients.
This study is closed
Do You Qualify?
| Have you been diagnosed with lupus? | Yes | No |
| Would you agree to discontinue your current immunosuppressant SLE medications and receive a brief course of IM steroids? | Yes | No |
| Should you qualify for this study, would you agree to use medically acceptable methods of contraception? | Yes | No |
| Are you pregnant or breast feeding or planning to become pregnant while enrolled in the study? | Yes | No |